Is there a place for chemotherapy in first line of treatment for metastatic NSCLC in era of immunotherapy?

D. I. Yudin; K. K. Laktionov

Medical alphabet
Medicinskij alfavit

ISSN 2078-5631 (Print)
ISSN 2949-2807 (Online)

User

eng | рус

Medical alphabet

Advanced search

Archives

Download this PDF file

Fullscreen

For citations:

Yudin D.I., Laktionov K.K. Is there a place for chemotherapy in first line of treatment for metastatic NSCLC in era of immunotherapy? Medical alphabet. 2022;(13):18-21. (In Russ.) https://doi.org/10.33667/2078-5631-2022-13-18-21

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2078-5631 (Print)
ISSN 2949-2807 (Online)

* not an advertisement

Indexing Databases

* not an advertisement

Popular articles Editors' Choice

Editor-in-Chief

Petrikov Sergey S.

Subscription Login to verify subscription

Article Tools

Finding References

Email this article (Login required)

Email the author (Login required)

About the Authors

D. I. Yudin
National Medical Research Centre of Oncology n. a. N. N. Blokhin
Russian Federation

Yudin Denis I., PhD Med, senior researcher

Moscow

K. K. Laktionov
National Medical Research Centre of Oncology n. a. N. N. Blokhin; Russian National Research Medical University n. a. N. I. Pirogov
Russian Federation

Laktionov Konstantin K., DM Sci (habil.), professor at Dept of Oncology and Radiation Therapy of Therapeutical Faculty, Russian National Research Medical University n. a. N. I. Pirogov; head of Dept of Oncological Medicinal Methods of Treatment (Chemotherapeutic) No. 17, National Medical Research Centre of Oncology n. a. N. N. Blokhin

Moscow

Notifications

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Medical alphabet

For citations:

Cookies policy